OSE Immunotherapeutics Showcases Novel FPR2 Agonist Approach to Advance Inflammatory Disease Treatment

OSE Immunotherapeutics declared that its abstract about a new agonist monoclonal antibody against the FPR2 receptor has been chosen to be presented at the AAI 2026 Annual Meeting in Boston. The treatment triggers an inflammatory resolution pathway that leads to resolution biology. The solution is meant to suppress the neutrophil build-up and treat chronic inflammatory ailments through an alternative mechanism to conventional immune suppression, its strategies.

Advancing a New Mechanism for Inflammation Resolution

Autoimmune and immune-mediated diseases are chronic inflammatory conditions, and they still constitute one of the most significant health issues worldwide, where most of these patients do not respond correspondingly to available treatment, or the side effects of treatment last for a long time. A promising alternative is the FPR2 agonist that OSE Immunotherapeutics has developed, which would help overcome these limitations at a crucial biological level. Preclinical evidence suggests that FPR2 activation results in decreased neutrophil accumulation - one of the major contributors to ongoing inflammation - and at the same time triggers processes that facilitate tissue healing and repair.

Dr. Aurore Morello, Chief Scientific Officer at OSE Immunotherapeutics, is the presenter of the research, and she will first unveil this novel approach. This new approach contrasts with the traditional treatment of anti-inflammatory agents, which primarily aim at inhibiting the immune process by actively promoting the natural activities of the body, correcting inflammation.

According to Precedence Research, the Inflammatory Disease Market size was calculated at USD 125.00 billion in 2025 and is predicted to increase from USD 133.50 billion in 2026 to approximately USD 241.34 billion by 2035, expanding at a CAGR of 6.80% from 2026 to 2035, driven by rising demand for high-technology solutions and therapies and the rising cases of chronic inflammatory diseases.

Industry Impact and Future Outlook

The development of inflammatory resolution pathway therapies is an indication of an overall trend in the biopharmaceutical industry of increasingly precise and mechanism-based interventions. The activities conducted by OSE Immunotherapeutics make the company a leader in the field of next-generation research of immuno-inflammation.